溶组织梭菌胶原酶市场（2026—2031）
溶组织梭菌胶原酶市场规模预计由2026年的1.5006亿美元增至2031年的2.1154亿美元，预测期复合年增长率为7.11%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
溶组织梭菌胶原酶市场规模预计由2026年的1.5006亿美元增至2031年的2.1154亿美元，预测期复合年增长率为7.11%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 7.11% | 机构预测 |
| 市场规模 | 2026 | USD 150.06 million | 机构预测 |
| 市场规模 | 2031 | USD 211.54 million | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end-user | hospitals | 2025 | 46.220% |
| formulation | liquid products | 2025 | 53.360% |
| indication | Dupuytren's contracture | 2025 | 41.720% |
关键结论
- end-user 维度中，hospitals 在 2025 年的公开份额为 46.22%。
- formulation 维度中，liquid products 在 2025 年的公开份额为 53.36%。
- indication 维度中，Dupuytren's contracture 在 2025 年的公开份额为 41.72%。
主要参与者
- Endo International plc
- Swedish Orphan Biovitrum AB (Sobi)
- Worthington Biochemical Corporation
- BioSpecifics Technologies Corp.
- Keenova Therapeutics plc
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Prevalence and Diagnosis of Fibrotic Hand and Urological Disorders | +1.800% | Global, concentrated in North America and Northern Europe | Medium term (2-4 years) |
| Shift Toward Minimally Invasive, Office-Based Treatment | +1.400% | North America and Europe, with spillover to APAC urban centers | Short term (≤ 2 years) |
| Expansion of CCH into New Fibrotic Indications | +1.100% | United States, followed by the European Union | Long term (≥ 4 years) |
| Increasing Specialist Familiarity and Procedure Standardization | +0.700% | North America, Germany, UK, and Australia | Medium term (2-4 years) |
| Aging Population and Accumulated Disease Burden | +1.000% | Global, with the highest effect in Japan, Western Europe, and North America | Long term (≥ 4 years) |
| Reimbursement and Specialty Pharmacy Infrastructure Maturation | +0.600% | North America and selected European markets | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Serious Procedure-Related Injury and Hypersensitivity Risk | -0.600% | Global, with highest clinical risk visibility in North America | Short term (≤ 2 years) |
| High Per-Course Treatment Cost and Reimbursement Friction | -0.800% | Europe excluding UK, Asia-Pacific emerging markets, and Latin America | Medium term (2-4 years) |
| Restricted Prescriber Access and Training Requirements | -0.500% | Asia-Pacific, Middle East and Africa, and South America | Medium term (2-4 years) |
| Concentrated Manufacturing and Cold-Chain Dependence | -0.300% | Asia-Pacific, Middle East and Africa, and South America | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for collagenase treatments?
Aging populations, improved diagnosis of fibrotic disorders, and demand for minimally invasive care support the demand. The market is valued at USD 140.70 million in 2025 to reach USD 150.06 million in 2026 and is forecasted to reach USD 211.54 million in 2031 at a 7.11% CAGR.
Which collagenase indication holds the largest share?
Dupuytren's contracture held 41.72% in 2025, supported by established clinical use and an extensive prescriber base.
Which collagenase application is growing the fastest?
Peyronie's disease is projected to grow at a 7.51% CAGR through 2031, supported by broader awareness and evidence for treatment during acute and stable phases.
Which region has the strongest growth outlook?
Asia-Pacific is forecasted to grow at a 9.24% CAGR through 2031, although reimbursement, regulatory progress, and supply infrastructure will shape actual uptake.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：高
查看来源：Mordor Intelligence